Cohen J S
Department of Psychiatry, University of California, San Diego, La Jolla 92093, USA.
Drug Saf. 2000 Jul;23(1):1-9. doi: 10.2165/00002018-200023010-00001.
Sildenafil is highly effective for treating erectile dysfunction (ED). However, its use has been associated with serious adverse events including myocardial infarctions and strokes, and 130 verifiable plus 112 unverified deaths reported to the US Food and Drug Administration during the 8 months after sildenafil was introduced in the US, and 522 reported deaths during the 13.5 months after its introduction. Moreover, some events have occurred in men taking their first dose of the agent, suggesting that sildenafil, like some drugs that affect blood pressure, may provoke a first-dose reaction. This possibility warrants extra caution to be used when initiating treatment with sildenafil. Such caution is not currently provided by the current dosage guidelines that, for example, recommend the use of sildenafil 50 mg initially for most men between the ages of 18 and 65 years, despite wide differences in bodyweight, age, drug metabolism, health status and usage of other medications. It can be difficult to identify the patient who may be unusually sensitive to the effects of sildenafil. Exercise stress tests have been recommended, but serious adverse events have occurred in men with normal stress tests following the ingestion of sildenafil. Blood pressure monitoring following sildenafil administration will not prevent a serious adverse drug event already in progress. This article discusses the advantages and disadvantages of initiating treatment with a low test dose of sildenafil, performed at home or in the doctor's office. The advantages of this approach include: (i) identifying patients who are highly sensitive to the effects of sildenafil and who may need no higher dose; (ii) minimising adverse effects such as flushing and dizziness that often frighten patients and may affect adherence; (iii) avoidance of major adverse events; and (iv) reassuring patients with ED who remain wary about trying sildenafil therapy.
西地那非在治疗勃起功能障碍(ED)方面疗效显著。然而,其使用与包括心肌梗死和中风在内的严重不良事件相关,在美国引入西地那非后的8个月内,有130例可核实的以及112例无法核实的死亡报告给了美国食品药品监督管理局,在引入后的13.5个月内报告了522例死亡。此外,一些事件发生在服用该药物首剂的男性身上,这表明西地那非与某些影响血压的药物一样,可能引发首剂反应。这种可能性使得在开始使用西地那非治疗时需要格外谨慎。目前的剂量指南并未提供此类谨慎建议,例如,对于大多数18至65岁的男性,尽管体重、年龄、药物代谢、健康状况和其他药物使用情况存在很大差异,但仍建议初始使用50毫克西地那非。很难识别出可能对西地那非作用异常敏感的患者。虽然有人推荐进行运动压力测试,但在服用西地那非后,压力测试正常的男性也发生了严重不良事件。服用西地那非后监测血压并不能预防已经发生的严重药物不良事件。本文讨论了在家中或医生办公室使用低测试剂量西地那非开始治疗的利弊。这种方法的优点包括:(i)识别出对西地那非作用高度敏感且可能无需更高剂量的患者;(ii)将诸如脸红和头晕等常常使患者害怕且可能影响依从性的不良反应降至最低;(iii)避免重大不良事件;(iv)让对尝试西地那非治疗仍持谨慎态度的ED患者放心。